27 May 2026VideosRegulation & IndustryJohn Rearick, Cooley | Sarah Hogan, Cooley | Mark Shtilerman, Deerfield Management | Jennifer Burdman, Sauvegarder Investment Management | Kumar Govindaswamy, Kymera Therapeutics

WATCH: IP deal-making in life sciences—valuation, due diligence, and transaction strategies

Structuring successful IP transactions in the life sciences sector requires rigorous due diligence and sophisticated valuation models. This panel brings together deal-makers and valuation experts to share strategies for protecting value and enabling innovation in complex M&A and licensing deals.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Regulation & Industry

Inside the deal boom: LSIPR’s five-part M&A series—all in one place

17 September 2026 Featuring interviews with dozens of lawyers, LSIPR published a five-part deep dive into the levers driving a surge in life sciences dealmaking. Author Marisa Woutersen discovered where buyers are placing their bets, what sellers can do to make themselves 'acquisition-ready', and why IP can make or break a deal.

Regulation & Industry

Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients

14 September 2026 Pitching for business has always been a partner’s game. One in-house team decided junior lawyers needed a seat at the table, building a programme to close an “industry-wide gap” in vital experience. Marisa Woutersen spoke with organisers Regeneron and associates from A&O Shearman, Hoyng Rokh Monegier, and Bristows, who stepped up to ‘sell’ their firms.

Regulation & Industry

Built to be bought? What makes companies acquisition-ready

11 September 2026 For biotech companies, promising science is no longer enough to attract a pharma buyer. Lawyers from Morrison Foerster, Polsinelli, Morgan Lewis and Dechert explain what makes an acquisition target truly deal-ready. Marisa Woutersen explores what companies should get right before a potential acquirer comes knocking.

More features

Leading European patent litigator to join Carpmaels & Ransford

CIPA Congress: Sustainability is essential for the profession and the planet

Non-profit sues Cambrex over anticancer drug manufacturing trade secrets

Inside the deal boom: LSIPR’s five-part M&A series—all in one place

Amgen hit with lawsuit over its proposed Opdivo biosimilar

Beyond the primary patent: How pharma can build competitive barriers

Australian biotech sues Grail over multi-cancer blood test

K&L Gates hires six-strong team of IP and corporate lawyers from Pillsbury

WATCH: IP deal-making in life sciences—valuation, due diligence, and transaction strategies

More on this story

Editor's picks

Editor's picks

More features